May 21, 2019 / 12:30PM GMT
Operator
Good day, ladies and gentlemen, and welcome to the BioCryst Pharmaceuticals' conference call. (Operator Instructions) As a reminder, this conference call is being recorded.
I would now like to introduce your host for today's conference, Mr. John Bluth at BioCryst. Sir, please go ahead.
John D. Bluth - BioCryst Pharmaceuticals, Inc. - SVP of IR & Corporate Communications
Thanks, Lauren. Good morning, and welcome to our call to discuss the top line results from the APeX-2 trial. A press release and accompanying slides are available on our website.
Participating with me today are CEO, Jon Stonehouse; Chief Medical Officer, Dr. Bill Sheridan; CFO, Tom Staab; and Chief Commercial Officer, Lynne Powell. Following our remarks, we'll answer your questions.
Before we begin, I want to direct your attention to Slide 2, which discusses our use of forward-looking statements and potential risk factors regarding an investment in BioCryst. As detailed on the slide, today's conference call will contain forward-looking statements, including those
BioCryst Pharmaceuticals Inc to Discuss APeX-2 Results Conference Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |

30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot
